The pharmaceutical company won antitrust approval after agreeing to sell rights and assets related to 79 generic drugs to rival firms.
REUTERS, NY Times: Business
Wed, 07/27/2016 - 4:25pm
The pharmaceutical company won antitrust approval after agreeing to sell rights and assets related to 79 generic drugs to rival firms.